MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Alvotech SA

Uždarymo kaina

SektoriusSveikatos priežiūra

8.2 0.61

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.01

Max

8.2

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-78M

32M

Pardavimai

40M

173M

P/E

Sektoriaus vid.

36.522

35.739

Pelno marža

18.494

Darbuotojai

1,012

EBITDA

-85M

52M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+95.36% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-49M

2.6B

Ankstesnė atidarymo kaina

7.59

Ankstesnė uždarymo kaina

8.2

Naujienos nuotaikos

By Acuity

50%

50%

149 / 371 reitingas Healthcare

Alvotech SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-15 14:54; UTC

Uždarbis

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Alvotech SA Prognozė

Kainos tikslas

By TipRanks

95.36% į viršų

12 mėnesių prognozė

Vidutinis 16 USD  95.36%

Aukščiausias 28 USD

Žemiausias 8 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Alvotech SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

4

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

149 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
help-icon Live chat